Literature DB >> 23850177

Comparison of the risks of opioid abuse or dependence between tapentadol and oxycodone: results from a cohort study.

M Soledad Cepeda1, Daniel Fife, Qianli Ma, Patrick B Ryan.   

Abstract

UNLABELLED: Tapentadol may have a lower abuse risk than other opioids because it has a relatively low affinity for the mu-opioid receptor. The aim of this retrospective cohort study was to compare the risk of opioid abuse between tapentadol immediate release (IR) and oxycodone IR using 2 claims databases (Optum and MarketScan). Subjects with no recent opioid use exposed to tapentadol IR or oxycodone IR in 2010 were followed for 1 year. The outcome was the proportion of subjects who developed opioid abuse, defined as subjects with International Classification of Diseases, 9th revision, codes for opioid abuse, addiction, or dependence. The relative odds of abuse were estimated using a logistic regression model with propensity-score stratification. The estimates from the 2 databases were pooled using a random effects model. There were 13,814 subjects in Optum (11,378 exposed to oxycodone, 2,436 exposed to tapentadol) and 25,553 in MarketScan (21,728 exposed to oxycodone, 3,825 exposed to tapentadol). The risk of abuse was higher in the oxycodone group than in the tapentadol group in each database. The pooled adjusted estimate for the odds of abuse was 65% lower with tapentadol than with oxycodone (odds ratio = .35, 95% confidence interval = .21-.58). The risk of receiving an abuse diagnosis with tapentadol was lower than the risk with oxycodone. Continued monitoring is warranted because opioid desirability can change over time. PERSPECTIVE: This study compared the risk of receiving an opioid abuse diagnosis between tapentadol and oxycodone in 2 U.S. claims databases. The risk of receiving an abuse diagnosis was lower with tapentadol during the year of follow-up. Opioid prescribers and patients must be aware of the risk of abuse associated with all opioids.
Copyright © 2013 American Pain Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Opioids; cohort studies; opioid abuse; opioid dependence; oxycodone; tapentadol

Mesh:

Substances:

Year:  2013        PMID: 23850177     DOI: 10.1016/j.jpain.2013.05.010

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  9 in total

1.  Perioperative Serum 25-Hydroxyvitamin D Levels as a Predictor of Postoperative Opioid Use and Opioid Use Disorder: a Cohort Study.

Authors:  Yuhree Kim; Fang Zhang; Katherine Su; Marc LaRochelle; Matthew Callahan; David Fisher; J Frank Wharam; Maryam M Asgari
Journal:  J Gen Intern Med       Date:  2020-06-24       Impact factor: 5.128

Review 2.  Multimechanistic Single-Entity Combinations for Chronic Pain Control: A Narrative Review.

Authors:  Joseph Pergolizzi; Peter Magnusson; Flaminia Coluzzi; Frank Breve; Jo Ann K LeQuang; Giustino Varrassi
Journal:  Cureus       Date:  2022-06-16

3.  Feasibility and utility of applications of the common data model to multiple, disparate observational health databases.

Authors:  Erica A Voss; Rupa Makadia; Amy Matcho; Qianli Ma; Chris Knoll; Martijn Schuemie; Frank J DeFalco; Ajit Londhe; Vivienne Zhu; Patrick B Ryan
Journal:  J Am Med Inform Assoc       Date:  2015-02-10       Impact factor: 4.497

Review 4.  Tapentadol extended release in the management of peripheral diabetic neuropathic pain.

Authors:  Nalini Vadivelu; Alice Kai; Benjamin Maslin; Gopal Kodumudi; Aron Legler; Jack M Berger
Journal:  Ther Clin Risk Manag       Date:  2015-01-14       Impact factor: 2.423

5.  Worldwide research productivity on tramadol: a bibliometric analysis.

Authors:  Waleed M Sweileh; Naser Y Shraim; Sa'ed H Zyoud; Samah W Al-Jabi
Journal:  Springerplus       Date:  2016-07-19

Review 6.  Tapentadol: Can It Kill Two Birds with One Stone without Breaking Windows?

Authors:  Eun Jung Chang; Eun Ji Choi; Kyung Hoon Kim
Journal:  Korean J Pain       Date:  2016-07-01

7.  Opioid use and harms associated with a sustained-release tapentadol formulation: a postmarketing study protocol.

Authors:  Amy Peacock; Briony Larance; Michael Farrell; Rose Cairns; Nicholas Buckley; Louisa Degenhardt
Journal:  BMJ Open       Date:  2018-03-23       Impact factor: 2.692

8.  Characterizing the Experience of Tapentadol Nonmedical Use: Mixed Methods Study.

Authors:  Suzanne K Vosburg; Taryn Dailey-Govoni; Jared Beaumont; Stephen F Butler; Jody L Green
Journal:  JMIR Form Res       Date:  2022-06-10

9.  Comparison of the risks of shopping behavior and opioid abuse between tapentadol and oxycodone and association of shopping behavior and opioid abuse.

Authors:  M Soledad Cepeda; Daniel Fife; Mary A Kihm; Greg Mastrogiovanni; Yingli Yuan
Journal:  Clin J Pain       Date:  2014-12       Impact factor: 3.442

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.